Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen To Present At The 2021 Piper Sandler Healthcare Conference

11/24/2021 | 04:01pm EST

THOUSAND OAKS, Calif., Nov. 24, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2021 Piper Sandler Healthcare Conference at 1:00 p.m. ET on Wednesday, Dec. 1, 2021. Murdo Gordon, executive vice president of Global Commercial Operations and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen 
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.  

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.  

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks 
Megan Fox, 805-447-1423 (media)
Trish Rowland, 805-447-5631 (media)
Arvind Sood, 805-447-1060 (investors) 

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-the-2021-piper-sandler-healthcare-conference-301431670.html

SOURCE Amgen


ę PRNewswire 2021
All news about AMGEN INC.
01/21Amgen - LUMAKRAS (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUT..
AQ
01/20AMGEN PLUGS IN : Electric Vehicle Pilot Program Advances Carbon Neutrality Goal
PU
01/20Amgen Secures Japanese Approval of Non-Small Cell Lung Cancer Drug Lumakras
MT
01/20Amgen Inc.'s LUMAKRAS Receives Approval in Japan for Patients with KRAS G12C-Mutated Ad..
CI
01/20"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
AQ
01/19FDA Clears CytomX's Investigational New Drug Application for CX-904 in Advanced Solid T..
MT
01/18Medicenna Therapeutics up 12.7% in US Trade, Details Management Change, Appoints Develo..
MT
01/14AMGEN : Teneobio Acquisition Adds Talent and New Types of Antibodies to Amgen
PU
01/13BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
DJ
01/13BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tu..
MT
More news
Analyst Recommendations on AMGEN INC.
More recommendations